Piper Sandler analyst David Westenberg downgraded Guardant Health to Neutral from Overweight with a price target of $50, down from $65. The analyst remains bullish on Guardant’s colorectal cancer screening offering but has concerns over the “event path of the stock as it moves to read out, a potential financing, and commercial and payor execution.” The best course of action for investors is to wait until after colorectal cancer screening sees early penetration, Westenberg tells investors in a research note.
previous post